Lytix Biopharma AS
Lytix is based in Norway, with offices in Tromsø and Oslo. The company was created as a spinout from the University of Tromsø and the University Hospital of Northern-Norway in 2003 and leverages more than 12 years of academic and industry research. Lytix’ core competences comprise methods to identify the pharmacophore of natural bioactive peptides and to convert them into small synthetic drug leads. Lytix maintains a close contact with the University of Tromsø and its expertise in medicinal chemistry, structural biology and bio prospecting. The development programs are supported by high-quality international service providers in key areas such as formulation, chemical scale-up and preclinical development. The company is well funded and intends to pursue a co-development and outlicensing strategy.
A Novel Cancer Immuno Therapy
Despite many advances being made over the past years, cancer remains one of the major causes of death in the western world. Lytix has developed a novel drug class based on the definition of the antimicrobial and anti-cancer pharmacophore of lactoferricin. Systematic QSAR work has resulted in the synthesis of a series of broadly active anti-tumor drugs. Our lead candidate LTX-315 shows efficacy across a range of 40 tumor cell lines, including those that are resistant to established chemotherapy. In vivo studies in syngeneic mice show the potential for a rapid induction of necrosis as well as an immune-mediated, complete and stable tumor response. LTX-315 is currently being tested in a phase 1 clinical trial for the treatment of solid tumors.
A Broad Spectrum Antimicrobial Agent
Lytix’ antimicrobial lead candidate (LTX-109) is designed to combat typical hospital infections such as methicillin-resistant Staphylococcus aureus (MRSA) as well as Streptococci and Pseudomonas. Intriguingly, the compound shows excellent efficacy also against various fungal and yeast species, underscoring it´s broadly effective biophysical mode of action. Efficacy of the product is not affected by established resistance, nor is there a propensity to develop new resistance in the strains tested. LTX-109 is currently being tested in a phase 2 clinical trial for the treatment of impetigo.
• Broad claims to novel pharmacophore
• Lytic – membrane lysing (biophysical) mode of action
• Low propensity for resistance
• Defined (membrane) target
• Broad spectrum of activity
• Outstanding efficacy in animal models
• Fully synthetic, low molecular weight drugs